Genfit S.A. (GNFT)
| Market Cap | 170.37M |
| Revenue (ttm) | 97.25M |
| Net Income (ttm) | 76.43M |
| Shares Out | 49.82M |
| EPS (ttm) | 1.28 |
| PE Ratio | 2.67 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,033 |
| Open | 3.43 |
| Previous Close | 3.35 |
| Day's Range | 3.37 - 3.48 |
| 52-Week Range | 3.01 - 6.38 |
| Beta | 1.24 |
| Analysts | Buy |
| Price Target | 9.43 (+175.7%) |
| Earnings Date | Jul 7, 2022 |
About GNFT
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test. Genfit S.A. was...
Analyst Forecast
According to 14 analysts, the average rating for GNFT stock is "Buy." The 12-month stock price forecast is 9.43, which is an increase of 175.73% from the latest price.
News
GENFIT Reports First Quarter 2022 Financial Information (Unaudited financial information under IFRS)
Lille, France; Cambridge, M A ; May 1 1 , 202 2 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseas...
GENFIT Announces Publication of the 2021 Universal Registration Document; the 2021 Annual Report on Form 20-F and Ava...
Lille, France; Cambridge, M A ; April 29 , 202 2 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver disea...
GENFIT Annual Combined General Meeting of May 25, 2022 — Availability of Preparatory Documents
Lille, France; Cambridge, M A ; April 20 , 202 2 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver disea...
What Makes GENFIT S.A. Unsponsored ADR (GNFT) a New Buy Stock
GENFIT S.A. Unsponsored ADR (GNFT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
GENFIT Reports Full-Year 2021 Financial Results and Provides Corporate Update
Lille, France; Cambridge, M A ; April 7 , 202 2 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseas...
GENFIT Announces Solid Revenues and Cash Position as of December 31, 2021
Lille, France; Cambridge , M A ; February 2 6 , 202 1 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver ...
GENFIT: 2022 Financial Calendar
Lille, France; Cambridge, MA; January 24, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver disease...
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
Lille, France; Cambridge, M A ; January 21 , 202 2 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic li...
Can GENFIT S.A. Unsponsored ADR (GNFT) Climb 79% to Reach the Level Wall Street Analysts Expect?
The consensus price target hints at a 78.9% upside potential for GENFIT S.A. Unsponsored ADR (GNFT).
How Much Upside is Left in GENFIT S.A. Unsponsored ADR (GNFT)?
The mean of analysts' price targets for GENFIT S.A. Unsponsored ADR (GNFT) points to a 59.9% upside in the stock.
These Biotech Penny Stocks Exploded Today, Here's Why
Which biotech penny stocks are you watching right now? The post These Biotech Penny Stocks Exploded Today, Here's Why appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
GNFT Stock Alert: 15 Things to Know About Biotech Penny Stock Genfit as Shares Go Gangbusters
Genfit (GNFT) stock is rocketing higher on Friday after the company signed an exclusive licensing agreement with Ipsen (IPSEY). The post GNFT Stock Alert: 15 Things to Know About Biotech Penny Stock Gen...
Why Genfit Shares Are Rising
Genfit SA (NASDAQ: GNFT) shares are trading higher after the company, and Ipsen, announced an exclusive licensing agreement for elafibranor. David Loew, Chief Executive Officer, Ipsen, said, "Today's an...
Genfit Shares Rally After Ipsen Buys Rights To Its Late-Stage Kidney Disease Treatment Hopeful
Ipsen SA (OTC: IPSEY) has entered into a long-term strategic partnership to develop, manufacture, and commercialize and Genfit SA's (NASDAQ: GNFT) elafibranor for Primary Biliary Cholangitis (PBC). Und...
On heels of global strategic partnership announced today, GENFIT acquires rights to novel asset
Lille, France; Cambridge, M A ; December 1 7 , 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic l...
GENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Pri...
GENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor , a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership
Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Bil...
PARIS--(BUSINESS WIRE)--Regulatory News: Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT (Nasdaq and Euronext: GNFT) have entered in...
GENFIT: FNIH NIMBLE Study Demonstrates NIS4® Technology's Unique Performance in Identifying Patients with “at-risk” NASH
Lille, France; Cambridge, M A ; November 18 , 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic li...
GENFIT Announces First Patient First Visit for the Evaluation of NTZ in Subjects with Hepatic Impairment as part of i...
Lille, France; Cambridge, M A ; November 09 , 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic li...
GENFIT: Third Quarter 2021 Financial Information
Lille, France; Cambridge, M A ; November 8 , 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liv...
New Clinical Data on GENFIT's Investigational Compound Elafibranor to be Presented at AASLD The Liver Meeting®
Lille, France; Cambridge, MA; November 0 2 , 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liv...
GENFIT Reports First Half-Year 2021 Financial Results and Provides Corporate Update
GENFIT Reports First Half-Year 2021 Financial Results and Provides Corporate Update
GENFIT: June 30, 2021 Annual Shareholders Meeting results
L ille (France) ; C ambridge ( M assachusetts, United States) — June 30 , 202 1 — GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients ...
GENFIT obtains non-dilutive financing of €11 million in the form of a State Guaranteed Loan
Lille, France; Cambridge, M A ; June 24 , 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases...
GENFIT presents new NIS4® data in NASH at the International Liver Congress™ and the 81st Scientific Sessions of the A...
Lille, France; Cambridge, M A ; June 2 3 , 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver disease...